Back to ALNYView Full Landscape
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
10 competitors in Alzheimer Disease
SAVASimufilam
Phase 3SNYxaliproden (SR57746A)
Phase 3SNYAVE1625
Phase 2NRSNPrimeC
Phase 2ALECAL002
Phase 2Drug Information
Target Indication
Alzheimer Disease
Mechanism of Action
RNAi Therapeutic
Clinical Trial
NCT05231785Last updated: 1/2/2026
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts